TICKERNERD
Menu
ERNAERNAHealthcare · Biotechnology

ERNA Stock Forecast: Ernexa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.78
+5.75% on the day

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. hold a median 12-month price target of $30 — +527.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.7M
Ticker Nerd rank
34 / 100
Median analyst target
$30
Analysts covering
1
Total return, dividends reinvested
1W
+11.9%
1M
+5.3%
YTD
−84.1%
1Y
−87.4%
From 52W high
−89.8%
From 52W low
+45.7%
$3
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ernexa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
91
Growth
52
Revisions
45
Issuance
44
Momentum
24
Value
18
Quality
16
Volatility
11

Size (94): Smaller than most of the companies we track.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ERNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26ERNAHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +527.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 May 2026Brookline CapitalInitiatesBuy$30
14 Dec 2022Morgan StanleyMaintainsEqual-Weight—
12 Dec 2022B of A SecuritiesUpgradeBuy—
14 Nov 2022NeedhamMaintainsBuy—
10 Aug 2022NeedhamMaintainsBuy—
15 July 2022Morgan StanleyMaintainsEqual-Weight—
12 May 2022JP MorganUpgradeOverweight—
11 May 2022NeedhamMaintainsBuy—
2 Mar 2022NeedhamMaintainsBuy—
11 Nov 2021NeedhamMaintainsBuy—
1 Oct 2021NeedhamMaintainsBuy—
16 June 2021Morgan StanleyMaintainsEqual-Weight—
13 May 2021NeedhamMaintainsBuy—
21 Apr 2021JP MorganInitiatesNeutral—
19 Apr 2021NeedhamMaintainsBuy—
26 Mar 2021Morgan StanleyInitiatesEqual-Weight—
25 Mar 2021NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ERNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Ernexa Therapeutics, Inc. (ERNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
1.8×

Cheaper than 51% of US stocks

EV / EBITDA
−0.3×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−320.7%

Higher than 5% of US stocks

Return on assets
−105.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ERNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERNAErnexa Therapeutics, Inc.$5.7M
34
APREAprea Therapeutics, Inc.$7.9M
44
AIMAIM ImmunoTech, Inc.$7.9M
20
TRAWTraws Pharma, Inc.$8.0M
48
AZTRAzitra, Inc.$8.0M
28
ACXPAcurx Pharmaceuticals, Inc.$7.7M
24
XBIOXenetic Biosciences, Inc.$8.2M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ernexa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERNA news & analysis

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

GlobeNewsWire · 10 Aug 2026positive

Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive with over 25 years of experience in oncology, capital markets, M&A, and corporate governance, to its board of directors as the company approaches the clinical stage.

Why it matters — The addition of a seasoned biotech founder and CFO to the board signals strengthened leadership and governance experience as Ernexa prepares to transition into a clinical-stage company.

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

GlobeNewsWire · 24 July 2026positive

Ernexa Therapeutics' CEO discussed the future of combination cancer therapies and explained how the company's drug candidate, ERNA-101, was designed to convert immunologically "cold" tumors into targets for the immune system.

Why it matters — An ERNA watcher would care because the CEO's comments highlight ERNA-101's potential role in combination cancer therapy, which could broaden its clinical applicability beyond standalone use.

FAQ

Frequently asked questions about ERNA stock

What is the ERNA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERNA stock a buy right now?

Of the 1 analysts covering Ernexa Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ernexa Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERNA?

As at 22 Aug 2026, Ernexa Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will ERNA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +527.6% from the last close, and Ticker Nerd's factor model ranks Ernexa Therapeutics, Inc. 34 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERNA stock forecast for 2030?

No analyst covering Ernexa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has ERNA stock performed over the past year?

Ernexa Therapeutics, Inc. returned -87.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ernexa Therapeutics, Inc. do?

Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company developing induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) therapies for oncology and autoimmune diseases.

What is the latest news on ERNA?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage". Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive with over 25 years of experience in oncology, capital markets, M&A, and corporate governance, to its board of directors as the company approaches the clinical stage.

Company

About Ernexa Therapeutics, Inc.

Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company developing induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) therapies for oncology and autoimmune diseases. Its lead program, ERNA-101, is an allogeneic pro-inflammatory cytokine-secreting iMSC designed to reprogram immunosuppressive tumor microenvironments and enhance T-cell anti-tumor activity, targeting solid tumors such as ovarian cancer. ERNA-102 and ERNA-201 focus on anti-inflammatory cytokine delivery for conditions like rheumatoid arthritis and other autoimmune disorders. The company's iMSC platform engineers cells to secrete targeted cytokines directly into tumors or inflamed tissues, addressing unmet needs in cell therapy. Eterna Therapeutics Inc. advances its pipeline through preclinical studies, regulatory engagements including Pre-IND meetings with the FDA, and manufacturing partnerships for clinical-grade production. Founded in 1984 and headquartered in Cambridge, Massachusetts, it leverages mRNA cell engineering technologies to repair cellular dysfunction across therapeutic indications.

CEO Mr. Sanjeev Luther · 5 employees · United States · https://www.ernexatx.com